Eyegate Pharmaceuticals Inc (EYEG): Capital Ii Ventech , 10% owner of Eyegate Pharmaceuticals Inc sold 29,400 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 9, 2016 to the Securities and Exchange Commission. The shares were sold at $3.24 per share for a total value of $95,423.60 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 7, 2016, Morton Goldberg (director) sold 10,939 shares at $3.31 per share price.On Feb 23, 2015, Paul G Chaney (director) purchased 8,333 shares at $6.00 per share price.Also, On Feb 23, 2015, Capital Ii Ventech (10% owner) purchased 102,777 shares at $6.00 per share price.On Feb 23, 2015, (innoven Partenaires S.a. Ipsa (10% owner) purchased 366,667 shares at $6.00 per share price.
Company has been under the radar of several Street Analysts.Eyegate Pharmaceuticals Inc is Initiated by Noble Financial to Buy and the brokerage firm has set the Price Target at $10. The Rating was issued on Apr 7, 2016.
Eyegate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437 is the first and only product in clinical trials and incorporates a reformulated topically active corticosteroid dexamethasone phosphate that is delivered into the ocular tissues though the Companys proprietary drug delivery system the EyeGate II Delivery System. EGP-437 is being developed under the 505(b)(2) New Drug Application (NDA) regulatory pathway for drugs submitted for approval to the United States Food and Drug Administration (FDA). The Company is also exploring the potential use of the EyeGate II Delivery System to provide a non-invasive solution for treating other more prevalent retinal diseases like age-related macular degeneration the two primary drug treatments.